However, DTYMK has been most thoroughly investigated in the context of hepatocellular carcinoma (HCC) and lung adenocarcinoma, wherein researchers extensively assessed the impact of inhibiting DTYMK or its knockdown on cancer cell behavior [43,44]. The gene discussed is DTYMK; the disease is hepatocellular carcinoma.